
via Monash University
- A world-first discovery by Australian researchers could become a game-changer for patients at risk of rapid health deterioration, such as heart complications, stroke, sepsis and cancer.
- Researchers developed an antibody as a biosensor, to continuously monitor rapid changes in the concentration of EGFR, a protein present on cancer cells and in body fluids.
- Traditional diagnostic tests involve sampling something tissue, blood or other bodily fluids, and taking it to a lab for further analysis. This new technique opens the door to monitor dynamic changes in real-time at the bedside.
A world-first discovery by researchers at Monash University and The University of Queensland could lead to faster and more effective treatments for chronic health complications, such as cardiovascular disease and cancer, with ‘fluorescent’ in vivo biosensors.
The research team, led by Dr Simon Corrie from Monash University’s Department of Chemical Engineering and the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, took an antibody that binds EGFR (epidermal growth factor receptor) proteins and engineered it to monitor the concentration of EGFR proteins in serum solutions over time.
Co-authors of the paper, published in ACS Sensors, are Dr Christian Fercher, Dr Martina Jones and Professor Stephen Mahler from The University of Queensland and the Australian Institute for Bioengineering and Nanotechnology.
An inability to detect the growth of EGFR proteins in humans can be associated with the development of a number of tumours, including cancer, as well as the onset of diseases like Alzheimer’s.
Using an independent detection mechanism developed by the research team, involving fluorescent dyes, researchers created a biosensor from a well-known antibody that was able to ‘read out’ changes of the EGFR protein in real-time by monitoring detectable changes in the fluorescence spectra.
The ability to monitor protein biomarker concentrations in body fluids in real-time is invaluable for tracking patients at risk of rapid deterioration, including those requiring personalised drug monitoring or those at high risk of complications arising from critical conditions, like sepsis, heart attack or tumour response to treatment.
No one has been able to engineer an antibody for continuous testing until now.
“All the diagnostic tests that we are familiar with involve sampling something (blood, urine, tissue) at a particular point in time and taking the same to a lab to interrogate it. But for patients suffering from acute conditions, in which time to diagnose and rapid treatment are very important, this traditional diagnostic process is not good enough,” Dr Corrie said.
“Monitoring dynamic changes in proteins, for example protein levels increasing or decreasing over time, is likely to provide much more detailed information about a disease or treatment process, but the sensors required to do this don’t exist outside of continuous glucose testing for diabetes.
“Our capacity to create antibodies, which bind reversibly to targets and can be ‘read out’ using fluorescence, means we can develop in vivo sensors. These sensors can monitor the levels of critical biomarkers as they change over time in response to a disease or treatment, rather than just sending a sample to a lab and getting a snapshot in a day or two.
“These biomarkers could include the amount of surface proteins on a cancer cell and whether or not a drug causes them to reduce in size, therefore testing the efficacy of treatment. It can also be used to monitor the concentration of potentially toxic drugs, like some antibiotics.”
This discovery was able to engineer an antibody fragment capable of reversibly binding to a protein analyte (scFv) in a chemical solution, while retaining the specificity of the original antibody sequence.
Through their efforts, continuous in vitro monitoring over multiple hours was successfully recorded.
“Work is underway to employ dyes that are much better suited to medical applications,” Dr Corrie said.
“In future, we expect that this process will be used to generate a range of biosensors that can monitor protein concentration continuously inside the human body, through a biopharmaceutical process, or in the environment.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Fluorescent in vivo biosensors
- Review of biosensing with whispering-gallery mode laserson February 26, 2021 at 1:07 am
Lasers are the pillars of modern optics and sensing. Microlasers based on whispering-gallery modes (WGMs) are miniature in size and have excellent lasing characteristics suitable for biosensing. WGM ...
- Analyte News and Researchon February 11, 2021 at 4:00 pm
with 'fluorescent' in vivo biosensors. In this interview, Ghaith Hamza from AstraZeneca talks to News-Medical Life Sciences about the basic principles of Affinity-Bead Assisted Mass Spectrometry ...
- Fluorescent Dyes News and Researchon February 3, 2021 at 4:00 pm
with 'fluorescent' in vivo biosensors. In Judith Su's Little Sensor Lab, researchers are working to sense tiny amounts - down to a single molecule - of everything from doping agents to biomarkers ...
- Making a tick protein talk as a serotonin sensoron February 1, 2021 at 4:00 pm
A genetically encoded neurotransmitter sensor, engineered from a tick lipocalin, detects serotonin in the living brain.
- Protein research provides breakthroughon January 25, 2021 at 4:46 am
But this new technique, which uses fluorescent dyes, opens the door to monitor dynamic changes in real time at the bedside, according to researchers. The biosensor is able to "read out" changes of ...
Go deeper with Google Headlines on:
Fluorescent in vivo biosensors
Go deeper with Bing News on:
Continuous biosensing
- Max-IR Labs Awarded $750K Phase II NSF SBIR Grant to Develop Real-Time Nitrogen Sensor for Wastewater Treatment Optimizationon March 1, 2021 at 5:00 am
Max-IR Labs, an infrared sensor technology company based in Dallas, Texas, announced it has been awarded a Phase II Small Business Innovation Research (SBIR) ...
- CVD Graphene for Electronic Applications: 2021 Status and Outlook from IDTechExon February 10, 2021 at 3:11 pm
The dream of CVD graphene is to grow a low cost, pure, perfect single layer in a continuous R2R production ... particularly in the biosensing/healthcare and photonic fields.
- Grapheal Raises EUR1.9 Million to Advance Development of Embedded Biosensing Technology and Application in Digital COVID Testing and Wound Monitoringon February 8, 2021 at 11:26 pm
About Grapheal Grapheal develops wearable and disposable sensors based on graphene that enables continuous monitoring and diagnosis. These flexible biosensors empower caregivers with an improved ...
- Data-Driven: How Technology Can Improve Psychiatric Practiceon February 3, 2021 at 3:47 pm
Still in its infancy, the field of technology in psychiatry is rapidly growing and holding much promise in diagnosis, symptom tracking, behaviorial reinforcement, and a host of other useful tools.
- Toward achieving precision healthon February 2, 2021 at 4:00 pm
Active participation in health care can be encouraged with continuous health-monitoring devices, providing a higher-resolution picture of human health and disease. However, the development of ...